Pancreatic Cancer Research

ResearcherTottori UniversityActive in the last 2 years

Yoshiyuki Fujiwara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3805-9003; OpenAlex author ID A5106176330. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 6 papers · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper

Papers 20

  1. Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer. Last author DOI 10.21873/anticanres.17509↗
  2. The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. Last author DOI 10.1007/s00595-024-02877-z↗
  3. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenoca… Last author DOI 10.1016/j.hpb.2024.03.603↗
  4. TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2022.101608↗
  5. High Glucose-stimulated aPKC Activation Promotes Pancreatic Cancer Cell Progression Through YAP Signaling. Co-author DOI 10.21873/anticanres.16681↗
  6. Current Value of Perioperative Therapies for Resectable or Borderline Resectable Pancreatic Cancer. Last author DOI 10.33160/yam.2023.05.014↗
  7. Modified geriatric nutritional risk index in patients with pancreatic cancer: a propensity score-matched analysis. Last author DOI 10.1186/s12885-022-10071-y↗
  8. Geriatric nutritional risk index as a prognostic factor in patients with recurrent pancreatic cancer. Last author DOI 10.1371/journal.pone.0271073↗
  9. Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer. Co-author DOI 10.1038/s41598-021-94711-6↗
  10. The prognostic significance of combined geriatric nutritional risk index and psoas muscle volume in older patients with pancreatic cancer. Last author DOI 10.1186/s12885-021-08094-y↗
  11. Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer. Last author DOI 10.1186/s12893-020-00976-5↗
  12. Cytoplasmic-only Expression of Maspin Predicts Unfavorable Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15032↗
  13. Evaluation of Blood Supply with Indocyanine Green Fluorescence in Resection for Concurrent Gastric and Pancreatic Cancer: A Case Report. Last author DOI 10.33160/yam.2021.02.017↗
  14. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.3390/cells10050985↗
  15. Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.11.028↗
  16. Sarcopenia as a prognostic factor in patients with recurrent pancreatic cancer: a retrospective study. Last author DOI 10.1186/s12957-020-01981-x↗
  17. Prognostic Impact of Pre- and Post-operative P-CRP Levels in Pancreatic Cancer Patients. Last author DOI 10.33160/yam.2020.02.011↗
  18. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer. Last author DOI 10.1016/j.hbpd.2019.03.010↗
  19. Preoperative Albumin-Bilirubin Grade as a Useful Prognostic Indicator in Patients With Pancreatic Cancer. Last author DOI 10.21873/anticanres.13260↗
  20. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Can… Last author DOI 10.21873/anticanres.12883↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teruhisa Sakamoto · 19 shared papers, 2018–2025 · strength 2.74
  2. Takehiko Hanaki · 14 shared papers, 2020–2024 · strength 2.07
  3. Masaki Morimoto · 10 shared papers, 2018–2023 · strength 1.21
  4. Yuki Murakami · 5 shared papers, 2021–2024 · strength 0.83
  5. Ei Uchinaka · 7 shared papers, 2018–2021 · strength 0.76
  6. Takuki Yagyu · 6 shared papers, 2019–2021 · strength 0.66
  7. Mikiya Kishino · 3 shared papers, 2024–2025 · strength 0.65
  8. Teppei Sunaguchi · 4 shared papers, 2022–2023 · strength 0.61
  9. Tatsuya Matsura · 3 shared papers, 2020–2023 · strength 0.45
  10. Joji Watanabe · 3 shared papers, 2019–2021 · strength 0.31
  11. Masataka Amisaki · 3 shared papers, 2018–2019 · strength 0.29
  12. Yoshihisa Umekita · 2 shared papers, 2020–2021 · strength 0.25
  13. Kazushi Hara · 1 shared paper, 2023 · strength 0.17
  14. Hajime Kurosaki · 1 shared paper, 2021 · strength 0.14
  15. Takafumi Nakamura · 1 shared paper, 2021 · strength 0.14
  16. Hiroyuki Kugoh · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.